Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder.

Next Previous
Trial Profile

Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Apr 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Guanfacine (Primary) ; Methylphenidate (Primary)
  • Indications Asperger syndrome; Autistic disorder; Hyperactivity; Mental retardation; Pervasive child development disorders
  • Focus Therapeutic Use

Most Recent Events

  • 04 Dec 2015 Treatment arm changed from 3 to 2 with removal of methylphenidate from the regimen as reported by ClinicalTrial.gov.
  • 29 Oct 2012 Planned End Date changed from 1 Mar 2013 to 1 Mar 2014 as reported by ClinicalTrials.gov.
  • 02 May 2012 Additional lead trial centre and investigator identified as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top